Inhibrx Biosciences Inc

INBX is entrenched in a Stage 4 decline, marked by sequential lower highs and lower lows beneath its down-sloping EMAs and the 50SMA. Relief rallies consistently stall and reverse at dynamic resistance, while oversold oscillators lack exhaustion. The medium-term bias remains bearish, so optimal execution is to sell into rallies toward the EMA/50SMA resistance zone via rejection.

• ↑FDA accepted Ozekibart's BLA, PDUFA target set for April 2027.
• ↑Ozekibart could address first systemic therapy gap in chondrosarcoma.
• ↓Negative P/E of –11.09 and latest EPS –$2.15 highlight deep losses.